Proposal to Add a New Article 5.5 and Article Title, and Add Sections 1747 and 1747.1 and Section Titles to Article 5.5 of Division 17 of Title 16 of the California Code of Regulations to read as follows:

Article 5.5. Pedigree Requirements.

1747. Unique Identification Number.

For the purposes of Section 4034 of the Business and Professions Code, the "unique identification number" that is to be established and applied to the smallest package or immediate container by the manufacturer or repackager as defined in subdivision (d) of Section 4034 shall conform to requirements for Standardized Numerical Identifiers (SNIs) set forth in a March 2010 publication by the U.S. Food and Drug Administration (FDA) titled “Guidance for Industry, Standards for Securing the Drug Supply Chain – Standardized Numerical Identification for Prescription Drug Packages,” (FDA’S Guidance Document), hereby incorporated by reference. As stated therein, an SNI consists of a serialized National Drug Code (NDC) product identifier combined with a unique numeric or alphanumeric serial number of no more than twenty (20) digits or characters. For dangerous drugs for which no NDC product identifier is assigned or is in use, an equivalent serialized product identifier may be used in place of the NDC consistent with the FDA's Guidance Document. This number shall be combined with a unique numeric or alphanumeric serial number that is not more than 20 digits or characters in length to establish the unique identification number.

This regulation shall become operative on January 1, 2015.


1747.1. Specification of Pedigreed Dangerous Drugs; Specification of Existing Stock

(a)(1) To comply with Business and Professions Code section 4163.5, each manufacturer of a dangerous drug distributed in California shall submit to the board, by December 31, 2014, a declaration signed under penalty of perjury by an owner, officer, or employee with authority to bind the manufacturer, containing the following:

Changes to the originally proposed language are shown as follows:

Deleted text is shown by double strike-through, thus: deleted language.
New or added text is shown by double underline, thus: added language.
(A) A list and quantity of dangerous drugs by name and product package (SKU) type representing at least fifty (50) percent of the manufacturer's total that are ready for initial implementation of the serialized electronic pedigree requirements as of January 1, 2015;

(B) A statement identifying which one of the following methods was used to measure the percentage of drugs ready to be serialized: (i) unit volume, (ii) product package (SKU) type, or (iii) drug product family;

(C) A statement describing the calculation(s) used to arrive at the percentage figure of dangerous drugs ready for serialized pedigree requirements;

(D) A list and quantity of dangerous drugs by name and product package (SKU) type that are in the remaining percentage not yet ready to be serialized or subject to pedigree requirements; and,

(E) a statement specifying the technology employed to meet the pedigree requirements, including but not limited to any platform(s), vendor(s), hardware, software, and communication technologies deployed.

(2) To comply with Business and Professions Code section 4163.5, each manufacturer of a dangerous drug distributed in California shall also submit to the board, by December 1, 2015, but no later than December 31, 2015, a declaration signed under penalty of perjury by an owner, officer, or employee with authority to bind the manufacturer, containing the following:

(A) A list and quantity of its remaining dangerous drugs by name and product package (SKU) type that are ready for implementation of serialized electronic pedigree requirements as of January 1, 2016.

(B) A statement identifying which one of the following methods was used to measure the final percentage of drugs to be serialized: (i) unit volume, (ii) product package (SKU) type, or (iii) drug product family;

(C) A statement describing the calculation(s) used to arrive at the final percentage figure; and,

(D) A statement specifying the technology employed to meet the pedigree requirements, including but not limited to any platform(s), vendor(s), hardware, software, and communication technologies deployed.

(3) Any failure to submit to the board a declaration compliant with subdivision (a)(1) by December 31, 2014, any failure to submit to the board a declaration compliant with subdivision (a)(2) by December 31, 2015, or any failure to re-submit either declaration to the board in fully compliant form within ten (10) days after notice of deficiency by the board, shall constitute a violation of the Pharmacy Law.

Changes to the originally proposed language are shown as follows:

Deleted text is shown by double strike-through, thus: deleted language.

New or added text is shown by double underline, thus: added language.
(b) For the purposes of Business and Professions Code sections 4163.2 and 4163.4, any manufacturer, wholesaler or repackager seeking to designate dangerous drugs it possesses, owns, or controls that are not subject to the serialized electronic pedigree requirements, shall submit to the Board, by no later than August 1, 2016, July 31, 2016, a declaration signed under penalty of perjury by an owner, officer, or employee with authority to bind the manufacturer, wholesaler or repackager, containing the following:

(1) a list and quantity of dangerous drugs by name, product package (SKU) type and National Drug Code (NDC) product identifier in the possession, ownership, or control of the manufacturer, wholesaler or repackager that were acquired prior to July 1, 2016;

(2) a statement that specifies the means and source of acquisition; and,

(3) a statement that specifies the anticipated means of any subsequent distribution or disposition.

(c) For the purposes of Business and Professions Code sections 4163.2 and 4163.4, any pharmacy or pharmacy warehouse seeking to designate dangerous drugs it possesses, owns, or controls that are not subject to the serialized electronic pedigree requirements, shall submit to the Board, by no later than August 1, 2017, July 31, 2017, a declaration signed under penalty of perjury by an owner, officer, or employee with authority to bind the pharmacy or pharmacy warehouse, containing the following:

(1) A list and quantity of dangerous drugs by name, product package (SKU) type and National Drug Code (NDC) product identifier in the possession, ownership, or control of the pharmacy or pharmacy warehouse that were acquired prior to July 1, 2017;

(2) A statement that specifies the means and source of acquisition; and,

(3) a statement that specifies the anticipated means of any subsequent distribution or disposition.

(d) The Board or its designee shall have sole discretion to determine whether any of the declarations submitted pursuant to this Section are compliant, and to reject and require re-submission of any non-compliant declaration(s) until determined to be fully compliant.

Note: Authority cited: Sections 4005, 4034, 4163, 4163.2 and 4163.5, Business and Professions Code. Reference: Sections 4034, 4034.1, 4163, 4163.1, 4163.2, 4163.4, 4163.5, Business and Professions Code.